{
    "nct_id": "NCT01083316",
    "title": "Phase II Trial of Induction Therapy With Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation in Patients With AL Amyloidosis",
    "status": "COMPLETED",
    "last_update_time": "2020-09-04",
    "description_brief": "The drugs dexamethasone and bortezomib are both FDA-approved for the treatment of multiple myeloma, a disease very similar to amyloidosis. However, they are currently investigational for the treatment of amyloidosis.\n\nWe want to find out if the addition of dexamethasone and bortezomib to standard high dose chemotherapy and stem cell transplant can help improve response.\n\nStandard treatment includes four steps: 1) Stem Cell Mobilization (standard) 2) Stem Cell Collection (standard) 3) Conditioning Regimen (Melphalan chemotherapy). The conditioning regimen helps to kill the abnormal cells in the body and makes room in the bone marrow for new blood stem cells to grow. 4) Stem Cell Infusion\n\nParticipants in this study will have an additional treatment step called \"induction therapy\", designed as the first step towards reducing the number of abnormal cells in the body. Two cycles of the investigational drugs bortezomib and dexamethasone will be given during induction therapy. In addition, bortezomib will given as part of the conditioning regimen, in addition to the standard melphalan chemotherapy.",
    "description_detailed": "The drugs dexamethasone and bortezomib are both FDA-approved drugs for the treatment of multiple myeloma, a disease very similar to amyloidosis. However, they are currently investigational for the treatment of amyloidosis.\n\nThe investigators want to find out if the addition of dexamethasone and bortezomib to standard treatment of high dose chemotherapy and stem cell transplant can help improve response to treatment.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "Bortezomib and Dexamethasone",
                    "description": "Induction:\n\nBortezomib (Velcade) 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days\n\nConditioning:\n\nBortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4 Melphalan 70-100 mg/m2/day IV on days -2 and -1\n\nBortezomib (Velcade) and Dexamethasone: Induction:\n\nVelcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days\n\nDexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days\n\nConditioning:\n\nBortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4\n\nMelphalan 70-100 mg/m2/day IV on days -2 and -1"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "35"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "32"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "3"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Bortezomib and Dexamethasone",
                    "description": "Induction:\n\nBortezomib (Velcade) 1.3 mg/m2/dose intravenous (IV) Days 1, 4, 8, 11 repeated every 21 days Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days\n\nConditioning:\n\nBortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4 Melphalan 70-100 mg/m2/day IV on days -2 and -1\n\nBortezomib (Velcade) and Dexamethasone: Induction:\n\nVelcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days\n\nDexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days\n\nConditioning:\n\nBortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4\n\nMelphalan 70-100 mg/m2/day IV on days -2 and -1"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "35"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Categorical",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "<=18 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Between 18 and 65 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "30"
                                        }
                                    ]
                                },
                                {
                                    "title": ">=65 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "5"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "22"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "13"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Number of Participants With Disease Response",
                    "description": "Complete response: Normal serum free light chain ratio and Negative serum and urine immunofixation electrophoresis Very good partial response: Difference in serum free light chains less than 40 mg/L Partial Response: \\>50% Reduction in the difference in serum free light chains",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "One year",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bortezomib and Dexamethasone",
                            "description": "Induction:\n\nBortezomib (Velcade) 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days\n\nConditioning:\n\nBortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4 Melphalan 70-100 mg/m2/day IV on days -2 and -1\n\nBortezomib (Velcade) and Dexamethasone: Induction:\n\nVelcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days\n\nDexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days\n\nConditioning:\n\nBortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4\n\nMelphalan 70-100 mg/m2/day IV on days -2 and -1"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "26"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "20"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Number of Participants Surviving at 100 Days Post Transplant",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "100 days",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bortezomib and Dexamethasone",
                            "description": "Induction:\n\nBortezomib (Velcade) 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days\n\nConditioning:\n\nBortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4 Melphalan 70-100 mg/m2/day IV on days -2 and -1\n\nBortezomib (Velcade) and Dexamethasone: Induction:\n\nVelcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days\n\nDexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days\n\nConditioning:\n\nBortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4\n\nMelphalan 70-100 mg/m2/day IV on days -2 and -1"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "30"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "27"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Number of Participants Proceeding to Transplant Following Induction",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "2 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bortezomib and Dexamethasone",
                            "description": "Induction:\n\nBortezomib (Velcade) 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days\n\nConditioning:\n\nBortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4 Melphalan 70-100 mg/m2/day IV on days -2 and -1\n\nBortezomib (Velcade) and Dexamethasone: Induction:\n\nVelcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days\n\nDexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days\n\nConditioning:\n\nBortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4\n\nMelphalan 70-100 mg/m2/day IV on days -2 and -1"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "35"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "30"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Number of Participants Surviving at 5 Years",
                    "populationDescription": "number of patients that completed at least one cycle of induction therapy",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "5 years",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bortezomib and Dexamethasone",
                            "description": "Induction:\n\nBortezomib (Velcade) 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days\n\nDexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days\n\nConditioning:\n\nBortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4\n\nMelphalan 70-100 mg/m2/day IV on days -2 and -1\n\nBortezomib: Induction:\n\nVelcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days\n\nConditioning:\n\nBortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4\n\nDexamethasone: Induction:\n\nDexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days\n\nMelphalan: Conditioning:\n\nMelphalan 70-100 mg/m2/day IV on days -2 and -1"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "35"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "29"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "timeFrame": "100 days",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Bortezomib and Dexamethasone",
                    "description": "Induction:\n\nBortezomib (Velcade) 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days\n\nConditioning:\n\nBortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4 Melphalan 70-100 mg/m2/day IV on days -2 and -1\n\nBortezomib (Velcade) and Dexamethasone: Induction:\n\nVelcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days\n\nDexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days\n\nConditioning:\n\nBortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4\n\nMelphalan 70-100 mg/m2/day IV on days -2 and -1",
                    "seriousNumAffected": 35,
                    "seriousNumAtRisk": 35,
                    "otherNumAffected": 35,
                    "otherNumAtRisk": 35
                }
            ],
            "seriousEvents": [
                {
                    "term": "autograft versus host disease",
                    "organSystem": "Immune system disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "neutropenic fever",
                    "organSystem": "Blood and lymphatic system disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 7,
                            "numAffected": 7,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "fever",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "CTCAE 4",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 7,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "Acute kidney failure",
                    "organSystem": "Renal and urinary disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "Adult Respiratory Distress Syndrome",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "cardiac arrest",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "creatinine increased",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "diarrhea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 15,
                            "numAffected": 15,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "Epstein Barr Virus-related Polymorphous Post Transplant Lymphoproliferative disorder",
                    "organSystem": "Blood and lymphatic system disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "epistaxis",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "fatigue",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 18,
                            "numAffected": 18,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "gastrointestinal bleed",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "hemorrhoidal hemmorhage",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "invasive aspirgillosis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "multiorgan failure",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "nausea",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 6,
                            "numAffected": 6,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "sepsis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "syncope",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 9,
                            "numAffected": 8,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "thrombocytopenia",
                    "organSystem": "Blood and lymphatic system disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "stomatitis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "skin rash",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "hypotension",
                    "organSystem": "Vascular disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 11,
                            "numAffected": 11,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "Dizziness",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 35
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "alkaline phosphatase elevated",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "drug rash",
                    "organSystem": "Blood and lymphatic system disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "tinnitus",
                    "organSystem": "Ear and labyrinth disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "nausea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 15,
                            "numAffected": 15,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "diarrhea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 14,
                            "numAffected": 14,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "adrenal insufficiency",
                    "organSystem": "Endocrine disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "constipation",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 13,
                            "numAffected": 13,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "anorexia",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 5,
                            "numAffected": 5,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "abdominal distension",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "hypotension",
                    "organSystem": "Vascular disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 8,
                            "numAffected": 8,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "alopecia",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 14,
                            "numAffected": 14,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "rash",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 7,
                            "numAffected": 7,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "dyspnea",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 10,
                            "numAffected": 10,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "sinus tachycardia",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 16,
                            "numAffected": 16,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "muscle weakness",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 5,
                            "numAffected": 5,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "dizziness",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 6,
                            "numAffected": 4,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "anxiety",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 12,
                            "numAffected": 7,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "Blurred vision",
                    "organSystem": "Eye disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 7,
                            "numAffected": 7,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "Abdominal pain",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "Bone pain",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 14,
                            "numAffected": 12,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "cough",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 7,
                            "numAffected": 6,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "peripheral edema",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 5,
                            "numAffected": 5,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "petechiae",
                    "organSystem": "Blood and lymphatic system disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 35
                        }
                    ]
                },
                {
                    "term": "oral mucositis",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "CTCAE (Unspecified)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 35
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": true
            },
            "pointOfContact": {
                "title": "Vaishali Sanchorawala",
                "organization": "Boston Medical Center",
                "email": "vaishali.sanchorawala@bmc.org",
                "phone": "6176386521"
            }
        }
    },
    "target_category": "disease-targeted small molecule",
    "drug": [
        "bortezomib",
        "dexamethasone"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The intervention is pharmacologic (bortezomib + dexamethasone) given to reduce or eradicate the clonal plasma cells that produce amyloidogenic light chains in AL (immunoglobulin light-chain) amyloidosis \u2014 i.e., the trial aims to modify the underlying disease process rather than to improve cognition or neuropsychiatric symptoms. \ue200cite\ue202turn1search2\ue202turn0search2\ue201",
        "Act: Key extracted details \u2014 drugs: bortezomib (a small\u2011molecule proteasome inhibitor) and dexamethasone (a corticosteroid). Bortezomib is FDA\u2011approved for multiple myeloma and acts by inhibiting the proteasome to induce plasma\u2011cell apoptosis; here it is repurposed in AL amyloidosis to target the pathogenic plasma\u2011cell clone and is used in induction and as part of conditioning before high\u2011dose melphalan and autologous stem cell transplant. \ue200cite\ue202turn0search1\ue202turn0search6\ue202turn0search2\ue201",
        "Reflect: Classification check \u2014 both agents are small\u2011molecule drugs (dexamethasone is a small\u2011molecule steroid; bortezomib is a small\u2011molecule proteasome inhibitor) used to target the disease biology (plasma cells producing toxic light chains). This fits the definition 'disease-targeted small molecule' (not a biologic, not a cognitive enhancer, and not a neuropsychiatric\u2011symptom treatment). No substantive ambiguity in classification based on the provided description. \ue200cite\ue202turn1search2\ue202turn0search9\ue201",
        "Web-search sources used (for verification/explanation): 1) FDA Velcade (bortezomib) information (mechanism/approval). \ue200cite\ue202turn0search1\ue201 2) Prospective trial reporting 2 cycles of bortezomib+dexamethasone induction followed by bortezomib+high\u2011dose melphalan and autologous SCT in AL amyloidosis (matches the trial title/description). \ue200cite\ue202turn0search2\ue202turn1search4\ue201 3) Review/early publications on bortezomib in myeloma (proteasome inhibitor mechanism). \ue200cite\ue202turn0search6\ue201 4) Pilot and other Phase II studies of bortezomib+dexamethasone around ASCT in AL amyloidosis supporting the same strategy. \ue200cite\ue202turn1search2\ue202turn0search3\ue201"
    ],
    "agent_type": "I) Proteostasis/Proteinopathies",
    "explanation_agent": [
        "Reason: The trial uses bortezomib (a small\u2011molecule proteasome inhibitor) plus dexamethasone to eradicate clonal plasma cells that produce pathogenic immunoglobulin light chains in AL (light\u2011chain) amyloidosis. This approach acts on production/turnover of an amyloidogenic protein (i.e., a proteostasis/proteinopathy mechanism), not on neurotransmission, vasculature, or purely symptomatic cognitive effects. \ue200cite\ue202turn0search3\ue202turn0search7\ue201",
        "Act: Extracted details \u2014 bortezomib (proteasome inhibitor; induces plasma\u2011cell apoptosis) and dexamethasone (corticosteroid) are used as induction and consolidation around high\u2011dose melphalan + autologous stem cell transplant in AL amyloidosis; the intervention therefore targets the disease biology that generates the amyloidogenic protein. Based on these mechanisms and targets, assign I) Proteostasis/Proteinopathies. \ue200cite\ue202turn0search3\ue202turn0search1\ue201",
        "Reflect: The classification fits CADRO category I because the therapeutic intent is to modify the production/clearance balance of a pathogenic amyloid protein by eliminating the plasma\u2011cell source \u2014 this is squarely a proteostasis/proteinopathy strategy rather than an Alzheimer-specific amyloid\u2011beta or tau intervention, nor is it a non\u2011therapeutic procedure. There is no indication of multiple distinct CADRO targets that would require R) Multi\u2011target. \ue200cite\ue202turn0search6\ue201",
        "Web\u2011search sources used (examples): FDA Velcade/bortezomib mechanism information (proteasome inhibitor). \ue200cite\ue202turn0search0\ue202turn0search3\ue201; Prospective clinical trials of bortezomib + dexamethasone induction with HDM/SCT in AL amyloidosis (Phase II / pilot and randomized studies). \ue200cite\ue202turn0search7\ue202turn0search1\ue202turn0search5\ue201"
    ]
}